You are here

  • Home
  • Archive
  • Volume 60, Issue Suppl 1
  • FRI0017 Infliximab (anti-tnf alpha antibody) treatment for rheumatoid arthritis: interim analysis of a spanish cohort study performed in routine practice. a multicenter open-label study of the catalonian society of rhematology, catalunya, spain

Citation Tools

Article menu
Download PDFPDF
Speaker abstracts 2001
Rheumatoid Arthritis – Treatment
FRI0017 Infliximab (anti-tnf alpha antibody) treatment for rheumatoid arthritis: interim analysis of a spanish cohort study performed in routine practice. a multicenter open-label study of the catalonian society of rhematology, catalunya, spain

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Carbonell J
FRI0017 Infliximab (anti-tnf alpha antibody) treatment for rheumatoid arthritis: interim analysis of a spanish cohort study performed in routine practice. a multicenter open-label study of the catalonian society of rhematology, catalunya, spain
Annals of the Rheumatic Diseases 2001;60:A452.